These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24812044)

  • 41. NICE and drugs for multiple sclerosis. National Institute of Clinical Excellence.
    Hartung HP
    Lancet; 2000 Sep; 356(9235):1114. PubMed ID: 11009171
    [No Abstract]   [Full Text] [Related]  

  • 42. [Disease modifying drugs in multiple sclerosis and pregnancy].
    Tur C; Tintoré M; Aguilera C
    Med Clin (Barc); 2012 Sep; 139(7):316-8. PubMed ID: 22743277
    [No Abstract]   [Full Text] [Related]  

  • 43. Benign multiple sclerosis: a distinct clinical entity with therapeutic implications.
    Pittock SJ; Rodriguez M
    Curr Top Microbiol Immunol; 2008; 318():1-17. PubMed ID: 18219812
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis.
    Zhang T; Tremlett H; Leung S; Zhu F; Kingwell E; Fisk JD; Bhan V; Campbell TL; Stadnyk K; Yu BN; Marrie RA;
    Neurology; 2016 Apr; 86(14):1287-1295. PubMed ID: 26944268
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A 29-year-old man with multiple sclerosis.
    Rudick RA
    JAMA; 1998 Oct; 280(16):1432-9. PubMed ID: 9801004
    [No Abstract]   [Full Text] [Related]  

  • 46. Options for multiple sclerosis therapy.
    Cotton P
    JAMA; 1994 Nov; 272(18):1393. PubMed ID: 7933404
    [No Abstract]   [Full Text] [Related]  

  • 47. More immunotherapy for multiple sclerosis.
    Hughes RA; Sharrack B
    J Neurol Neurosurg Psychiatry; 1996 Sep; 61(3):239-41. PubMed ID: 8795592
    [No Abstract]   [Full Text] [Related]  

  • 48. Multiple sclerosis. Generic glatiramer acetate--a step toward cheaper MS drugs?
    Sørensen PS
    Nat Rev Neurol; 2016 Jan; 12(1):5-6. PubMed ID: 26635211
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Therapeutic compliance of first line disease-modifying therapies in patients with multiple sclerosis. COMPLIANCE Study.
    Saiz A; Mora S; Blanco J;
    Neurologia; 2015 May; 30(4):214-22. PubMed ID: 24484756
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current and future role of interferon beta in the therapy of multiple sclerosis.
    Farrell RA; Giovannoni G
    J Interferon Cytokine Res; 2010 Oct; 30(10):715-26. PubMed ID: 20874249
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Genetic Markers for Personalized Therapy of Polygenic Diseases: Pharmacogenetics of Multiple Sclerosis].
    Tsareva EY; Favorova OO; Boyko AN; Kulakova OG
    Mol Biol (Mosk); 2019; 53(4):574-599. PubMed ID: 31397433
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Glatiramer acetate induced acute exacerbation of autoimmune hepatitis in a patient with multiple sclerosis.
    Neumann H; Csepregi A; Sailer M; Malfertheiner P
    J Neurol; 2007 Jun; 254(6):816-7. PubMed ID: 17351724
    [No Abstract]   [Full Text] [Related]  

  • 53. [Not Available].
    Bourgeois F
    Rev Infirm; 2016 Mar; (219):45-6. PubMed ID: 26944649
    [No Abstract]   [Full Text] [Related]  

  • 54. [Interferon beta treatment in multiple sclerosis].
    Ochi H
    Nihon Rinsho; 2003 Aug; 61(8):1367-73. PubMed ID: 12962025
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Disease-modifying treatments in multiple sclerosis].
    Confavreux C; Bouhour F; Vukusic S
    Rev Prat; 1999 Nov; 49(17):1882-9. PubMed ID: 10598505
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The multiple sclerosis market.
    Huynh T
    Nat Rev Drug Discov; 2010 Oct; 9(10):759-60. PubMed ID: 20885402
    [No Abstract]   [Full Text] [Related]  

  • 57. Current disease-modifying therapies in multiple sclerosis.
    Kieseier BC; Hartung HP
    Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Switching for convenience from first-line injectable treatments to oral treatments in multiple sclerosis: Data from a retrospective cohort study.
    Buard G; Giovannelli J; Outteryck O; Hadhoum N; Lannoy J; Vermersch P; Zéphir H
    Mult Scler Relat Disord; 2019 Aug; 33():39-43. PubMed ID: 31152966
    [No Abstract]   [Full Text] [Related]  

  • 59. The emergence of follow-on disease-modifying therapies for multiple sclerosis.
    Moss BP; Cohen JA
    Mult Scler; 2019 Oct; 25(12):1560-1565. PubMed ID: 31074707
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.